Medicine
Isturisa 1 mg tablet
Isturisa 1 mg tablet is a prescription medicine containing Osilodrostat for oral use, marketed by Recordati Rare Diseases, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at room temperature between 20°C to 25°C (68°F to 77°F), excursions…
Key facts
- Active ingredient (INN)
- Osilodrostat
- Brand
- Isturisa
- Strength
- 1 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 20 tablets, 60 tablets and 1 more
- Marketing authorisation holder
- Recordati Rare Diseases
- Manufacturer
- Recordati Rare Diseases
- Origin register
- US FDA, United States
- Storage
- Store at room temperature between 20°C to 25°C (68°F to 77°F), excursions permitted 15°C to 30°C (59°F to 86°F), protect from moisture.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- H02CA02 Osilodrostat
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 31 March 2020
- Identifiers
- RxCUI 2286275, 2286281, 2286283 +3DailyMed set ID f3a5ec24-63c3-4d83-b1c0-6c550fbe7ae2NDC 55292-320, 55292-330Application NDA212801
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 20 tablet, coated in 1 blister pack | 55292-320-20 | Recordati Rare Diseases | 31 March 2020 |
| 60 tablet, coated in 1 blister pack | 55292-320-60 | Recordati Rare Diseases | 31 March 2020 |
| 20 tablet, coated in 1 blister pack | 55292-330-20 | Recordati Rare Diseases | 3 November 2025 |
| 60 tablet, coated in 1 blister pack | 55292-330-60 | Recordati Rare Diseases | 3 November 2025 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Osilodrostat
Clinical summary
Osilodrostat is a cortisol synthesis inhibitor indicated for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative. MedsAcross supplies Osilodrostat for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about OsilodrostatFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Isturisa prescribing information (Recordati Rare Diseases) · U.S. National Library of Medicine, DailyMed
- Isturisa: European public assessment report (EPAR) · European Medicines Agency
Need Isturisa 1 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.